Physician profile
David E Vann
NPI 1760466742
$2,584.51
in general payments reported to CMS, 2019-2025
33 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $837 · 2020: $233 · 2021: $14.87 · 2022: $463 · 2023: $95.00 · 2024: $470 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,006 · Education: $30.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.71 |
| Education | $30.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $325.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $268.27 | 2019-2025 | |
| Novo Nordisk INC | $245.32 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $239.90 | 2019-2025 | Shingrix, Arexvy |
| Radius Health, INC. | $167.96 | 2019 | |
| Abbvie INC. | $150.53 | 2019-2025 | Vraylar |
| Astrazeneca Pharmaceuticals Lp | $141.20 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.59 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $104.29 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $101.69 | 2024-2025 | Gemtesa |
| Dexcom, INC. | $96.82 | 2023-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.99 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $80.64 | 2019-2020 | |
| Amgen INC. | $60.32 | 2019-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $37.95 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $37.15 | 2022 | |
| Sunovion Pharmaceuticals INC. | $34.39 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.12 | 2023 | Trintellix |
| Axsome Therapeutics, INC. | $29.59 | 2024 | Auvelity |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.47 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $28.23 | 2019-2022 | |
| Genentech USA, INC. | $24.25 | 2019 | |
| Bausch Health US, LLC | $22.26 | 2024 | Wellbutrin, Aplenzin |
| Neos Therapeutics, Lp | $18.71 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.30 | 2022 | |
| Mylan Specialty L.P. | $16.11 | 2020 | |
| Dynavax Technologies Corporation | $16.02 | 2025 | Heplisav-B |
| Merck Sharp & Dohme LLC | $13.40 | 2019 | |
| Allergan, INC. | $12.79 | 2019 | |
| Horizon Therapeutics Plc | $11.95 | 2020 | |
| Mannkind Corporation | $11.18 | 2019 | |
| Shire North American Group INC | $10.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Vann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.